Envestnet Asset Management’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.26M Buy
75,460
+12,036
+19% +$1.2M ﹤0.01% 2054
2025
Q4
$6.17M Sell
63,424
-3,596
-5% -$308K ﹤0.01% 2033
2025
Q3
$4.77M Sell
67,020
-83
-0.1% -$5.53K ﹤0.01% 2270
2025
Q2
$4.01M Sell
67,103
-3,370
-5% -$185K ﹤0.01% 2337
2025
Q1
$3.7M Buy
70,473
+11,892
+20% +$668K ﹤0.01% 2336
2024
Q4
$3.22M Buy
58,581
+2,909
+5% +$153K ﹤0.01% 2385
2024
Q3
$2.8M Buy
55,672
+2,786
+5% +$129K ﹤0.01% 2457
2024
Q2
$2.32M Buy
52,886
+206
+0.4% +$8.76K ﹤0.01% 2501
2024
Q1
$2.32M Buy
+52,680
New +$2.33M ﹤0.01% 2480
2017
Q3
Sell
-510
Closed -$4K 2970
2017
Q2
$4K Hold
510
﹤0.01% 2872
2017
Q1
$5K Sell
510
-1,337
-72% -$12.4K ﹤0.01% 2900
2016
Q4
$21K Sell
1,847
-3
-0.2% -$32 ﹤0.01% 2656
2016
Q3
$31K Buy
+1,850
New +$34.3K ﹤0.01% 2730

Other funds holding IRMD

Envestnet Asset Management's IRMD Position: Q1 2026 in Review

Envestnet Asset Management increased its iRadimed (IRMD) stake by 19% in Q1 2026, buying an estimated $1.2M and bringing the position to 75,460 shares worth $7.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Envestnet Asset Management first reported a position in IRMD in Q3 2016 and has held it in 13 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Envestnet Asset Management held 75,460 shares of iRadimed worth $7.26M as of Q1 2026.
  • Envestnet Asset Management bought 12,036 iRadimed shares in Q1 2026, an estimated $1.2M.
  • iRadimed made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #2054 holding.
  • Envestnet Asset Management first reported a position in iRadimed in Q3 2016 and has held it in 13 quarters since.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.